Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
10.44
+0.04 (0.38%)
At close: Apr 28, 2026, 4:00 PM EDT
10.43
-0.01 (-0.10%)
After-hours: Apr 28, 2026, 7:10 PM EDT
Telix Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Telix Pharmaceuticals stock have an average target of 21.13, with a low estimate of 20 and a high estimate of 22.5. The average target predicts an increase of 102.39% from the current stock price of 10.44.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Telix Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $22 | Buy | Reiterates | $22 | +110.73% | Apr 13, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +91.57% | Apr 13, 2026 |
| Wedbush | Wedbush | Buy Reiterates $22 | Buy | Reiterates | $22 | +110.73% | Apr 7, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +91.57% | Apr 7, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $22 → $23 | Strong Buy | Maintains | $22 → $23 | +115.52% | Feb 24, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.